Alkermes Inc. and Alza Corp. were to announce today that they have agreed to develop and commercialize RMP-7, ALKS's permeation enhancing agent to deliver drugs across the blood-brain barrier.

The deal is the second this year between the two companies, and could bring AZA's total investment in its ALKS partnership to $110 million. In February, AZA gained a 9.7 percent interest in ALKS through the purchase of $50 million newly issued, unregistered shares of ALKS. Simultaneously, the companies agreed to develop and commercialize an undisclosed product using one of two of ALKS' drug delivery technologies, ProLease or Medisorb.